Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis : Narrative Review
Girolomoni, Giampiero (University of Verona)
Savage, Laura (University of Leeds)
Gisondi, Paolo (University of Verona)
Svensson, Åke (Skåne University Hospital, Lund University)
Mahé, Emmanuel (Hospital Victor-Dupouy)
Augustin, Matthias (University Medical Center Hamburg-Eppendorf)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona

Data:	2023
Resum:	Psoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence ranging between 0. 51 and 11. 43%. It results in a large clinical and social burden, with patients frequently suffering from reduced quality of life, psychologic distress and debilitating comorbidities. Biologic agents are used to establish and maintain disease control in patients with moderate-to-severe psoriasis and are essential to improving quality of life. However, a substantial proportion of patients have limited access to therapy due to economics, health policies and clinical considerations, which creates clinical unmet needs that disadvantage both patients and healthcare professionals. Biosimilars are a cost-effective alternative to off-patent biologic therapies, and there is mounting evidence to suggest they offer a valuable pharmacoeconomic strategy to lower healthcare costs in patients with psoriasis. Furthermore, the introduction of biosimilars can increase the number of patients able to receive biologics, allowing these patients to be treated earlier in the disease course, potentially modifying the course of their disease and reducing the risk of comorbidities. In time, the emergence of additional data, particularly those related to long-term safety, efficacy in extrapolated indications and the effects of switching, should reassure physicians and help overcome the final hurdles for a wider implementation of biosimilars. This review aims to provide an overview of current treatment approaches for patients with moderate-to-severe psoriasis in the biosimilars era and explores both the current challenges and potential opportunities to improve access to high-quality, effective treatments.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Biologic drugs ; Biosimilars ; Unmet needs ; Moderate-to-severe ; Psoriasis
Publicat a:	Dermatology and Therapy, Vol. 13 (september 2023) , p. 2171-2185, ISSN 2190-9172

DOI: 10.1007/s13555-023-01014-x
PMID: 37710078

15 p, 347.0 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats